The pan-tumor landscape of gene amplifications and copy number amplification ratio for established and emerging clinical targets

CN amplifications are prevalent and diverse biomarkers and AmpRatio is variable across genes and tumor types. ERBB2 AmpRatio is associated with outcomes to HER2-directed therapies and may have utility alongside IHC for clinical decision making. With the increasing number of therapies targeting amplifications/overexpression, it will be important to define harmonized methods for CN quantification for optimal patient selection.

Authors

Institutions

Publication Details

Journal
Clinical Cancer Research
Published
2026-03-23
DOI
https://doi.org/10.1158/1078-0432.ccr-25-4018
Primary Topic
Lung Cancer Treatments and Mutations
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

The pan-tumor landscape of gene amplifications and copy number amplification ratio for established and emerging clinical targets

Matthew R. Strickland, Ryon P. Graf, Tess A. O’Meara, Bernard J. Fendler et al.
Clinical Cancer Research
Lung Cancer Treatments and Mutations
article

The pan-tumor landscape of gene amplifications and copy number amplification ratio for established and emerging clinical targets

Matthew R. Strickland, Ryon P. Graf, Tess A. O’Meara, Bernard J. Fendler, Alexa B. Schrock, Samuel Jacob Klempner, Candice Francheska B. Tambaoan, Amaya Gascó Hernández, Maryam B. Lustberg, Harshabad Singh, L. Pusztai, Julia C. F. Quintanilha, Jessica K. Lee, Richard S.P. Huang, Sara M. Tolaney, Ethan S. Sokol, Jeffrey Ross, Nicole Odzer, Kuei-Ting Chen, Brennan Decker, Timothy A. Yap
article en

Abstract

CN amplifications are prevalent and diverse biomarkers and AmpRatio is variable across genes and tumor types. ERBB2 AmpRatio is associated with outcomes to HER2-directed therapies and may have utility alongside IHC for clinical decision making. With the increasing number of therapies targeting amplifications/overexpression, it will be important to define harmonized methods for CN quantification for optimal patient selection.

Clinical Cancer Research
The University of Texas MD Anderson Cancer Center (US), SUNY Upstate Medical University (US), Boston Foundation (US), Yale University (US), Massachusetts General Hospital (US), Dana-Farber Cancer Institute (US), Yale New Haven Health System (US), PHG Foundation (GB), Emergency Medicine Foundation (US), Cardiovascular Clinical Science Foundation (US), 1675 Foundation (US), Veterans Medical Research Foundation of San Diego (US)
Peace, Justice and strong institutions
Openalex Percentile: Top 13%
Lung Cancer Treatments and Mutations
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.